MedTrace Logo

Evaluation of a Peptide Cream on the Forearm Skin Recovery of Healthy Volunteers

NCT07614698 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-05-29

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate the efficacy of a topical peptide-based formulation containing Acetyl Hexapeptide-37 in promoting skin barrier recovery after controlled disruption in healthy adult participants.

The main questions it aims to answer are:

* Does the peptide cream speed up the recovery of the skin barrier after it has been slightly damaged with tape-stripping method?
* How does the peptide cream compare to a placebo (a cream with no active ingredient) in improving skin hydration and reducing redness?

Researchers will compare the peptide cream to a placebo to assess its effects on skin barrier recovery

Participants will:

* Undergo controlled disruption of the skin barrier on the volar forearm using the tape-stripping method.
* One forearm will receive the peptide-based cream containing Acetyl Hexapeptide-37, while the other (contralateral) forearm will receive a placebo formulation.
* Attend scheduled visits for non-invasive assessments of skin barrier function, including transepidermal water loss, skin hydration, and erythema

Conditions

  • Skin Barrier Disruption and Recovery

Interventions

OTHER

Acetyl Hexapeptide-37

The emollient cream contains Acetyl Hexapeptide-37 as the active ingredient and is applied topically to designated skin areas on the forearm. Skin barrier disruption is induced prior to application using the tape-stripping method. Procedure will be performed on healthy, intact skin according to randomization protocol

OTHER

Placebo

The emollient cream without the peptide is applied topically to designated skin areas on the forearm. Skin barrier disruption is induced prior to application using the tape-stripping method. Procedure will be performed on healthy, intact skin according to randomization protocol

Sponsors & Collaborators

  • University of Split, School of Medicine

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2027-01-31
Completion
2027-01-31

Countries

  • Croatia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07614698 on ClinicalTrials.gov